RNA Prakiraan rega marang bathi Avidity Biosciences Inc
Avidity Biosciences (RNA) develops innovative RNA-based therapeutics in US laboratories, targeting the genetics of diseases. The company's estimated forward P/E on this GURU.Markets platform chart confirms this stability, where 0.00 characterizes this valuation parameter. Protection against replication is ensured by elite patents on conjugates, while a sophisticated infrastructure and a unique intellectual property portfolio support high business margins.
Rincian analitis perusahaan Avidity Corp (RNA)
- kuotasi lan prakiraan analis:
- data kapitalisasi pasar:
- statistik nilai buku emiten:
- informasi babagan utang lan solvabilitas:
Total Utang marang Modal Avidity Biosciences|RNA - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Avidity Biosciences|RNA - Gunggung kewajiban utang perusahaan|Rasio utang marang kapitalisasi buku Avidity Biosciences Inc|RNA - Utang jangka dawa|Utang jangka cendhak perusahaan Avidity Biosciences|Rasio cepet aviditybiosciences.com
- rincian asil keuangan lan kelipatan valuasi:
RNA - Penghasilan resik|Proyeksi bathi mangsa ngarep Avidity Biosciences|RNA - Periode bali modal bisnis|Pangali Forward P/E Avidity|RNA - Rega marang bathi kanthi panyesuaian wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Avidity Biosciences Inc|RNA - Bathi operasional sadurunge amortisasi|Bathi resik saben saham (EPS TTM) Avidity Biosciences|RNA - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan aviditybiosciences.com|RNA - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Avidity Biosciences
Analisis dhasar perusahaan:RNA Avidity Biosciences, Inc.
Fundamental risks for Avidity Biosciences (RNA) are assessed through the ratio of market capitalization to projected net income, which allows for the determination of the asset's fair value. By analyzing the company's expected P/E ratio, an investor compares current development costs for unique RNA drugs with the potential for monopoly pricing power upon successful clinical trials, identifying entry points with an optimal balance of price and future returns.
Pesaing Avidity Biosciences (RNA)
Pangali Forward P/E TEM|Kapitalisasi marang proyeksi bathi Qiagen NV|Ionis Pharma - Prakiraan rega marang bathi|Rasio kapitalisasi marang bathi mangsa ngarep RGEN (Repligen Inc.)|CRSP: Prakiraan rega marang bathi|Rasio prakiraan rega marang bathi genedx.com|RARE (Ultragenyx) - Prakiraan rega marang bathi|Beam Therapeutics Inc - Pangali mangsa ngarep rega marang bathi|SRPT (Sarepta Therapeutics Inc) - Pangali Forward P/E|Rega marang bathi mangsa ngarep TWST|Pangali Forward P/E TXG|Kapitalisasi marang proyeksi bathi intelliatx.com|Rega marang bathi mangsa ngarep Stoke Therapeutics, Inc. STOK|BioLife Solutions Inc (BLFS) - Rasio prakiraan rega marang bathi|WVE - Rega marang bathi mangsa ngarep|Kapitalisasi marang proyeksi bathi Maze Therapeutics Corp MAZE|SION: Pangali Forward P/E|Prakiraan rega marang bathi primemedicine.com|TSHA (Taysha Gene Therapies, Inc.) - Pangali Forward P/E|uniQure NV (QURE) - Kapitalisasi marang proyeksi bathi|Pangali Forward P/E MGTX|RGNX - Rasio prakiraan rega marang bathi|Rega marang bathi mangsa ngarep Solid Biosciences Inc. SLDB|OCGN: Rasio rega marang bathi mangsa ngarep|PacBio - Pangali Forward P/E|Benitec Biopharma Inc (BNTC) - Prakiraan rega marang bathi|DSGN: Pangali Forward P/E|Rasio prakiraan rega marang bathi Rocket Corp (RCKT)|Rega marang bathi mangsa ngarep 4D Molecular Therapeutics|Lexeo (LXEO) - Kapitalisasi marang proyeksi bathi|Rega marang bathi mangsa ngarep Korro Bio, Inc. (KRRO)|EDIT (Editas Medicine Inc) - Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep Silence Therapeutics Inc. SLN|PRQR: Rasio rega marang bathi mangsa ngarep|Codexis Bio - Pangali Forward P/E|SGMO - Pangali Forward P/E|NAUT: Pangali Forward P/E|Rasio rega marang bathi mangsa ngarep MGX|Rega marang bathi mangsa ngarep Precision BioSciences, Inc.|Rasio rega marang bathi mangsa ngarep GBIO (Generation Bio Corp)|Pangali Forward P/E BOLD|Pangali Forward P/E exicuretx.com (XCUR)|Pangali Forward P/E IMNN (Imunon)|Pangali Forward P/E Phio Pharmaceuticals Corp PHIO|MBIO: Prakiraan rega marang bathi|RNAZ: Rega marang bathi mangsa ngarep|BNGO: Pangali Forward P/E|APDN - Kapitalisasi marang proyeksi bathi|BLUE (bluebird bio) - Pangali Forward P/E|Rasio rega marang bathi mangsa ngarep IPA (ImmunoPrecise)|Pangali Forward P/E OMGA|Kapitalisasi marang proyeksi bathi Singular Genomics Corp|Regulus Therapeutics - Prakiraan rega marang bathi|Rasio kapitalisasi marang bathi mangsa ngarep SYRS (syros.com)|TBIO: Prakiraan rega marang bathi|Rasio prakiraan rega marang bathi TRACON Pharmaceuticals Inc.|UBX (Unity Bio) - Prakiraan rega marang bathi
